Hyaluronic acid (topical): Difference between revisions
Kiran Singh (talk | contribs) No edit summary |
m Protected "Hyaluronic acid (topical)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
(20 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
|authorTag={{KS}} | |authorTag={{KS}} | ||
|genericName=hyaluronic acid | |||
|aOrAn=a | |aOrAn=a | ||
| | |drugClass=musculoskeletal agent | ||
|adverseReactions= | |indicationType=treatment | ||
|indication=[[osteoarthritis]] of knee, hair growth and loss prevention | |||
|adverseReactions=injection site pain, injection site reaction , [[arthralgia]] | |||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | ||
Line 12: | Line 15: | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult====== | |fdaLIADAdult===Indications== | ||
===Hyaluronic Acid Solution=== | |||
* | * For hair growth and loss prevention | ||
'''Dosage''' | |||
* Spray on the scalp 2~3 times daily as needed | |||
* Recommendable to apply enough on the scalp prior to going to bed | |||
===Hyaluronic Acid Injection=== | |||
* Osteoarthritis of knee | |||
'''Dosage''' | |||
* | * Osteoarthritis of knee: 30 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 3 to 4 injections (as a series of 3 to 4 injections each 1 week apart). | ||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |||
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | |||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |||
|warnings=* Stop using and see a doctor if any hypersensitivity symptom continues | |||
* Avoid storing under direct sun light or high temperature | |||
|clinicalTrials='''Dermatologic''': Injection site pain, Injection site reaction | |||
: | '''Musculoskeletal''': [[arthralgia]] | ||
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label. | |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label. | ||
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category''' | |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category''' | ||
Line 264: | Line 58: | ||
<!--Administration and Monitoring--> | <!--Administration and Monitoring--> | ||
|administration=* | |administration=* IV | ||
:*Attach a small gauge needle (18- to 21-gauge) to tip of the syringe; inject the full contents of syringe into one knee only. | |||
* | :*If treatment is bilateral, use a separate syringe for each knee. | ||
* | * For hair scalp spraying only | ||
|monitoring=* Reduction in pain associated with [[osteoarthritis]] of the knee is indicative of efficacy | |||
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label. | |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label. | ||
|drugBox=[[File:Hyaluronic acid drug.png|thumb|none|600px|This image is provided by the National Library of Medicine.]] | |||
|drugBox= | |||
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. | |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. | ||
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label. | |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label. | ||
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label. | |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label. | ||
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label. | |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label. | ||
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | ||
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
|brandNames=* Orthovisc | |||
* Monovisc | |||
|brandNames=* | * Morisu | ||
|drugShortage= | |drugShortage= | ||
}} | }} | ||
{{LabelImage}} | |||
{{LabelImage | |||
}} | |||
{{LabelImage | {{LabelImage | ||
|fileName= | |fileName=Hyaluronic acid ingredients and appearance.png | ||
}} | }} | ||
<!--Pill Image--> | <!--Pill Image--> | ||
Line 349: | Line 93: | ||
<!--Category--> | <!--Category--> | ||
[[Category:Glycosaminoglycans]] | |||
[[Category:Drug]] | [[Category:Drug]] |
Latest revision as of 16:28, 20 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Hyaluronic acid (topical) is a musculoskeletal agent that is FDA approved for the treatment of osteoarthritis of knee, hair growth and loss prevention. Common adverse reactions include injection site pain, injection site reaction , arthralgia.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
Hyaluronic Acid Solution
- For hair growth and loss prevention
Dosage
- Spray on the scalp 2~3 times daily as needed
- Recommendable to apply enough on the scalp prior to going to bed
Hyaluronic Acid Injection
- Osteoarthritis of knee
Dosage
- Osteoarthritis of knee: 30 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 3 to 4 injections (as a series of 3 to 4 injections each 1 week apart).
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (topical) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (topical) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Hyaluronic acid (topical) in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (topical) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (topical) in pediatric patients.
Contraindications
There is limited information regarding Hyaluronic acid (topical) Contraindications in the drug label.
Warnings
- Stop using and see a doctor if any hypersensitivity symptom continues
- Avoid storing under direct sun light or high temperature
Adverse Reactions
Clinical Trials Experience
Dermatologic: Injection site pain, Injection site reaction
Musculoskeletal: arthralgia
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Hyaluronic acid (topical) in the drug label.
Drug Interactions
There is limited information regarding Hyaluronic acid (topical) Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Hyaluronic acid (topical) in women who are pregnant.
Pregnancy Category (AUS):
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hyaluronic acid (topical) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Hyaluronic acid (topical) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Hyaluronic acid (topical) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Hyaluronic acid (topical) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Hyaluronic acid (topical) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Hyaluronic acid (topical) in patients who are immunocompromised.
Administration and Monitoring
Administration
- IV
- Attach a small gauge needle (18- to 21-gauge) to tip of the syringe; inject the full contents of syringe into one knee only.
- If treatment is bilateral, use a separate syringe for each knee.
- For hair scalp spraying only
Monitoring
- Reduction in pain associated with osteoarthritis of the knee is indicative of efficacy
IV Compatibility
There is limited information regarding IV Compatibility of Hyaluronic acid (topical) in the drug label.
Overdosage
There is limited information regarding Hyaluronic acid (topical) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Mechanism of Action
There is limited information regarding Hyaluronic acid (topical) Mechanism of Action in the drug label.
Structure
There is limited information regarding Hyaluronic acid (topical) Structure in the drug label.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Hyaluronic acid (topical) in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Hyaluronic acid (topical) in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Hyaluronic acid (topical) in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Hyaluronic acid (topical) in the drug label.
How Supplied
There is limited information regarding Hyaluronic acid (topical) How Supplied in the drug label.
Storage
There is limited information regarding Hyaluronic acid (topical) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Hyaluronic acid (topical) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Hyaluronic acid (topical) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Hyaluronic acid (topical) in the drug label.
Precautions with Alcohol
- Alcohol-Hyaluronic acid (topical) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Orthovisc
- Monovisc
- Morisu
Look-Alike Drug Names
There is limited information regarding Hyaluronic acid (topical) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Label Page=Hyaluronic acid (topical) |Label Name=
}}
{{#subobject:
|Label Page=Hyaluronic acid (topical) |Label Name=Hyaluronic acid ingredients and appearance.png
}}